Condition: Fabry Disesase · Sponsor: GC Biopharma Corp
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
This description comes directly from the study's public registry record.
GC Biopharma · +82-031-260-9300 · GC1134A@gccorp.com
Always discuss trial participation with your own doctor first.
| David Geffen School of Medicine UCLA, UCLA Health | Los Angeles, California, United States | Recruiting |
| University of Kansas School of Medicine | Kansas City, Kansas, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Pittsburgh Medical Center Children's Hoispital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Lysosomal and Rare Disorders Research and Treatment Center | Fairfax, Virginia, United States | Recruiting |
| Centro Medico IPAM | Rosario, Santa Fe Province, Argentina | Recruiting |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | Recruiting |
| Pusan National University Children's Hospital in Yangsan | Yangsan, Gyeongsangnam-do, South Korea | Recruiting |
| Yonsei University, College of Medicine | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06858397